MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
